Paula is responsible for the IFPMA Influenza Vaccine Supply International Task Force, leading pathogen sharing policy and advocacy efforts for the pharmaceutical industry.
Prior to joining IFPMA, Paula worked for GSK in different global marketing and commercial roles, including vaccines and rare diseases.
Paula has a MSc in Global Health Policy from the London School of Hygiene and Tropical Medicine, a Master in Pharmaceutical Marketing from Universitat Pompeu Fabra, Barcelona, and a PharmD in Pharmaceutical Sciences from the University of Porto, Portugal.
Our ability to prepare for and respond to pandemics swiftly rests on improved global pathogen surveillance, immediate information and data sharing, and the scientific community’s ability to collaborate efficiently and effectively.
More from Paula
Vaccines are crucial to lifelong health and future global health security
Childhood vaccination is recognized as one of the greatest medical success stories of the 20th century. Apart from clean water, no other intervention has had a bigger impact on global public health, especially for children, their families, and communities. In fact, vaccines have done such a good job of eradicating, eliminating or controlling certain infectious diseases that many of us have forgotten, or no longer worry, that our children or loved ones might still contract diseases like polio, measles or diphtheria.
Flu season 2021/22 is approaching: flu vaccination may be more important than ever to protect the most vulnerable
Last flu season was exceptionally mild because of the measures used to contain COVID-19, like physical distancing and masks. But what will the upcoming flu season look like?
Harmonizing regulatory requirements to accelerate the supply of vaccines
This blog was originally published on the Media Planet Campaign Value of Vaccines on 25 June 2021. Over the past few decades, the global regulatory environment has become more stringent and demanding to consistently guarantee the quality, safety and efficacy of medicines and vaccines. The increase in requirements by regulatory authorities has not been implemented...